Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.

NCT Number	NCT06975410
Lead Sponsor	Yuhan Corporation
Conditions	EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
Enrollment	80 participants
Start Date	2025-06-12
Primary Completion	2027-06 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-10